Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Semifluorinated alkanes (SFA, e.g. perfluorobutylpentane F4H5, perfluorohexyloctane F6H8) are inert, non-toxic fluids capable of dissolving lipophilic drugs. The aim of this study to assess the bioavailability and safety of SFAs as drug solvents for the topical ocular application of Cyclosporin A (CsA). A commercially available CsA formulation (Restasis, 0.05% CsA in castor oil) was tested against two novel formulations of 0.05% CSA in (a) F4H5 containing Ethanol (0.5 w/w%) and (b) F6H8 containing Ethanol (0.5 w/w%) with 0.05% CsA. Formulations were tested on rabbit corneas cultured on an artificial anterior chamber with a constant flow of an aqueous humour supplement (Ex Vivo Eye Irritation Test (EVEIT) system). Anterior chamber fluids were sampled at multiple time points to analyse the CsA concentration following single and repeated application regimes by HPLC. Photographs of fluorescein sodium-stained corneas were recorded for corneal toxicity evaluation. The impact of the formulations on the integrity of the corneal barrier function was tested after drug application by fluorescein sodium corneal diffusion experiments. The influence on the corneal metabolism was evaluated by analysis of the metabolic markers glucose and lactate. Restasis did not pass the corneal barrier after short term application, CsA in ethanolic F4H6 reached a maximum of 152.95 ng/ml in anterior chamber fluid samples whilst CsA in ethanolic F6H8 reached a maximum of 15.12 ng/ml. After repeated applications for 8h, Restasis reached 21.07 ng/ml compared to 247.62 ng/ml and 174.5 ng/ml for F4H5 and F6H8, respectively. No corneal toxicity was observed in following application of any of the formulations. In contrast to the commercially available castor oil-based formulation, CsA dissolved in SFAs reached therapeutic inner ocular concentrations after topical administration, possibly leading to the replacement of systemic applications of CsA for inflammatory ocular disease.
Aachen Centre Of Technology Transfer In Ophthalmology (ACTO e.V.), An-Institute, RWTH Aachen University, Germany. Electronic address: dutescumichael@googlemail.com.
R M
RM
Dutescu
Aachen Centre Of Technology Transfer In Ophthalmology (ACTO e.V.), An-Institute, RWTH Aachen University, Germany.
C
C
Panfil
Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA.
O M
OM
Merkel
Aachen Centre Of Technology Transfer In Ophthalmology (ACTO e.V.), An-Institute, RWTH Aachen University, Germany.
N
N
Schrage
D000287:Administration, Topical; D000473:Alkanes / Q000737:chemistry*; D000818:Animals; D002368:Castor Oil / Q000737:chemistry; D003315:Cornea / Q000187:drug effects*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000737:chemistry; D004337:Drug Carriers; D005123:Eye / Q000187:drug effects*; D005128:Eye Diseases / Q000188:drug therapy; D019793:Fluorescein / Q000737:chemistry; D005461:Fluorine / Q000737:chemistry*; D005947:Glucose / Q000737:chemistry; D007249:Inflammation / Q000188:drug therapy; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry; D008055:Lipids / Q000737:chemistry*; D011817:Rabbits; D012997:Solvents / Q000737:chemistry
D000473:Alkanes; D004337:Drug Carriers; D008055:Lipids; D012997:Solvents; D005461:Fluorine; D019344:Lactic Acid; D002368:Castor Oil; D016572:Cyclosporine; D005947:Glucose; D019793:Fluorescein
Cyclosporine; EVEIT; Ex vivo model; Ocular drug delivery; Ocular pharmacokinetics; Semifluorinated alkanes